TY - JOUR T1 - Re-evaluating the evidence for fecal microbiota transplantation “super-donors” in inflammatory bowel disease JF - medRxiv DO - 10.1101/19011635 SP - 19011635 AU - Scott W. Olesen AU - Ylaine Gerardin Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/11/12/19011635.abstract N2 - Fecal microbiota transplantation (FMT) is a recommended treatment for recurrent Clostridioides difficile infection, and there is promise that FMT may be effective for conditions like inflammatory bowel disease (IBD). Previous FMT clinical trials have considered the possibility of a “donor effect”, that is, that FMT material from different donors has different clinical efficacies. Here we lay out rigorous statistical methodology for detecting donor effects, finding that reliable detection of a donor effect requires trials with more than 200 FMT-treated patients. A re-evaluation of previous FMT clinical trials for IBD showed that while there is very little evidence for a non-zero donor effect, the existing data are also not inconsistent with substantial donor effects. Large-scale meta-analysis, combined with careful reporting from clinical trials, will be crucial in determining if donor effects are clinically relevant for IBD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSWO is an employee of OpenBiome. YG is an employee of Finch Therapeutics. No other funding was used for any aspect of the submitted work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesComputer code and underlying data to reproduce the results are online at https://www.github.com/openbiome/donor-effects. https://www.github.com/openbiome/donor-effects ER -